Literature DB >> 21178011

A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells.

Angel N Morrow1, Hana Schmeisser, Takaya Tsuno, Kathryn C Zoon.   

Abstract

Type I (e.g., IFN-α, IFN-β) and type II IFNs (IFN-γ) have antiviral, antiproliferative, and immunomodulatory properties. Both types of IFN signal through the Jak/STAT pathway to elicit antiviral activity, yet IFN-γ is thought to do so only through STAT1 homodimers, whereas type I IFNs activate both STAT1- and STAT2-containing complexes such as IFN-stimulated gene factor 3. In this study, we show that IFN-stimulated gene factor 3 containing unphosphorylated STAT2 (ISGF3(II)) also plays a role in IFN-γ-mediated antiviral activity in humans. Using phosphorylated STAT1 as a marker for IFN signaling, Western blot analysis of IFN-α2a-treated human A549 cells revealed that phospho-STAT1 (Y701) levels peaked at 1 h, decreased by 6 h, and remained at low levels for up to 48 h. Cells treated with IFN-γ showed a biphasic phospho-STAT1 response with an early peak at 1-2 h and a second peak at 15-24 h. Gene expression microarray following IFN-γ treatment for 24 h indicated an induction of antiviral genes that are induced by IFN-stimulated gene factor 3 and associated with a type I IFN response. Induction of these genes by autocrine type I and type III IFN signaling was ruled out using neutralizing Abs to these IFNs in biological assays and by quantitative RT-PCR. Despite the absence of autocrine IFNs, IFN-γ treatment induced formation of ISGF3(II). This novel transcription factor complex binds to IFN-stimulated response element promoter sequences, as shown by chromatin immunoprecipitation analysis of the protein kinase R promoter. STAT2 and IFN regulatory factor 9 knockdown in A549 cells reversed IFN-γ-mediated IFN-stimulated response element induction and antiviral activity, implicating ISGF3(II) formation as a significant component of the cellular response and biological activity of IFN-γ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178011      PMCID: PMC3417313          DOI: 10.4049/jimmunol.1001359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses.

Authors:  H A Bluyssen; R Muzaffar; R J Vlieststra; A C van der Made; S Leung; G R Stark; I M Kerr; J Trapman; D E Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

2.  Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1.

Authors:  G S Foss; H Prydz
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

3.  Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway.

Authors:  M H Heim; I M Kerr; G R Stark; J E Darnell
Journal:  Science       Date:  1995-03-03       Impact factor: 47.728

4.  Interferon regulatory factor 1 induces the expression of the interferon-stimulated genes.

Authors:  Y C Henderson; M Chou; A B Deisseroth
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

5.  Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase.

Authors:  M C Gauzzi; L Velazquez; R McKendry; K E Mogensen; M Fellous; S Pellegrini
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

6.  Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA.

Authors:  H A Bluyssen; D E Levy
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

Review 8.  Immune defence in mice lacking type I and/or type II interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; R M Zinkernagel; M Aguet
Journal:  Immunol Rev       Date:  1995-12       Impact factor: 12.988

9.  Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Interaction between the components of the interferon gamma receptor complex.

Authors:  S V Kotenko; L S Izotova; B P Pollack; T M Mariano; R J Donnelly; G Muthukumaran; J R Cook; G Garotta; O Silvennoinen; J N Ihle
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

View more
  33 in total

Review 1.  The role of signal transducer and activator of transcription-2 in the interferon response.

Authors:  Håkan C Steen; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2012-01-26       Impact factor: 2.607

2.  Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection.

Authors:  Kevin B O'Brien; Stacey Schultz-Cherry; Laura J Knoll
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

3.  STAT1β is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity.

Authors:  Christian Semper; Nicole R Leitner; Caroline Lassnig; Matthias Parrini; Tanel Mahlakõiv; Michael Rammerstorfer; Karin Lorenz; Doris Rigler; Simone Müller; Thomas Kolbe; Claus Vogl; Thomas Rülicke; Peter Staeheli; Thomas Decker; Mathias Müller; Birgit Strobl
Journal:  Mol Cell Biol       Date:  2014-04-07       Impact factor: 4.272

4.  Antiviral activity of salmonid gamma interferon against infectious pancreatic necrosis virus and salmonid alphavirus and its dependency on type I interferon.

Authors:  Baojian Sun; Ingrid Skjæveland; Tina Svingerud; Jun Zou; Jorunn Jørgensen; Børre Robertsen
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

Review 5.  The JAK-STAT pathway at twenty.

Authors:  George R Stark; James E Darnell
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

6.  Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus.

Authors:  Markus J Hofer; Wen Li; Peter Manders; Rachael Terry; Sue Ling Lim; Nicholas J C King; Iain L Campbell
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons.

Authors:  Isabella Rauch; Felix Rosebrock; Eva Hainzl; Susanne Heider; Andrea Majoros; Sebastian Wienerroither; Birgit Strobl; Silvia Stockinger; Lukas Kenner; Mathias Müller; Thomas Decker
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

Review 8.  STAT2 and IRF9: Beyond ISGF3.

Authors:  Karin Fink; Nathalie Grandvaux
Journal:  JAKSTAT       Date:  2013-12-18

9.  The Interferon-Gamma Paradox in Cancer.

Authors:  M Raza Zaidi
Journal:  J Interferon Cytokine Res       Date:  2018-11-09       Impact factor: 2.607

10.  Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis.

Authors:  William Alazawi; Helen Heath; Jennifer A Waters; Abigail Woodfin; Alastair J O'Brien; Anthony J Scarzello; Bin Ma; Yolanda Lopez-Otalora; Michael Jacobs; Gemma Petts; Robert D Goldin; Sussan Nourshargh; Ana M Gamero; Graham R Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.